Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

31.3%

5 terminated/withdrawn out of 16 trials

Success Rate

64.3%

-22.2% vs industry average

Late-Stage Pipeline

13%

2 trials in Phase 3/4

Results Transparency

11%

1 of 9 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

10(62.5%)

Phase 2

4(25.0%)

Phase 3

2(12.5%)

16Total

Phase 1(10)

Phase 2(4)

Phase 3(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT01510288Phase 1Terminated

Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer

Role: collaborator

NCT00577356Phase 2Terminated

Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer

Role: collaborator

NCT00122005Phase 1Unknown

GVAX in Advanced Prostate Cancer Patients Made Lymphopenic

Role: collaborator

NCT00089856Phase 3Terminated

GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer

Role: lead

NCT00109655Phase 1Unknown

Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure

Role: lead

NCT00133224Phase 3Terminated

Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients

Role: lead

NCT00140348Phase 1Completed

Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine

Role: lead

NCT00116441Phase 1Completed

Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma

Role: lead

NCT00089726Phase 2Completed

A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)

Role: lead

NCT00116467Phase 2Completed

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Role: lead

NCT00103428Phase 1Terminated

Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer

Role: lead

NCT00245362Phase 2Completed

A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

Role: lead

NCT00140374Phase 1Completed

Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)

Role: lead

NCT00140400Phase 1Completed

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer

Role: lead

NCT00140387Phase 1Completed

Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)

Role: lead

NCT00116155Phase 1Completed

Trial of IV Injection of CV787 in Hormone Refractory Metastatic Prostate Cancer

Role: lead

All 16 trials loaded